Virbac entered into an agreement to use ProBioGen's avian cell lines to develop biological product candidates.
Under the terms of the licensing deal, Virbac will use the permanent cell lines based on duck retina AGE1.cr and somite cells AGE1.cs.
"This is a breakthrough in the commercialization of our avian cell line," notes Michael Schlenk, CEO of ProBioGen. "The development of new designer cell lines under the full guidelines of the FDA is a long and challenging process. We are very proud to have developed such a cell line, which not only satisfies these stringent requirements, but is also safe and cost effective for vaccine and biological production."